Trial Title:
Anti-CD19 Chimeric Antigen Receptor T-Cell Immunotherapy for Chronic Lymphocytic Leukemia (CLL)
NCT ID:
NCT06364423
Condition:
B-Cell Chronic Lymphocytic Leukemia
Leukemia, Lymphocytic, Chronic, B-Cell
B-Lymphocytic Leukemia, Chronic
Conditions: Official terms:
Leukemia
Leukemia, Lymphoid
Leukemia, Lymphocytic, Chronic, B-Cell
Leukemia, B-Cell
Cyclophosphamide
Rituximab
Fludarabine
Conditions: Keywords:
Chimeric Antigen Receptors
Autologous T Cells Infusion
Adoptive T Cell Therapy
Gene Therapy
Small Lymphocytic Lymphoma
Chronic Lymphocytic Leukemia
Immunotherapy
Study type:
Interventional
Study phase:
Phase 1/Phase 2
Overall status:
Recruiting
Study design:
Allocation:
Non-Randomized
Intervention model:
Sequential Assignment
Primary purpose:
Treatment
Masking:
None (Open Label)
Intervention:
Intervention type:
Biological
Intervention name:
Autologous HuCD19 ( Anti-CD19)CAR T cells
Description:
1.0x10^6 CAR+T-cells - 12x10^6 CAR+ T cells/kg (weight based dosing per cohort) infused
on day 0
Arm group label:
1/Rituximab, conditioning chemotherapy plus CAR T-cells- Dose escalation
Arm group label:
2/Rituximab, conditioning chemotherapy plus CAR T-cells- Dose expansion
Intervention type:
Drug
Intervention name:
Cyclophosphamide
Description:
500 mg/m^2 IV infusion over 30 minutes on days -5, -4 and -3
Arm group label:
1/Rituximab, conditioning chemotherapy plus CAR T-cells- Dose escalation
Arm group label:
2/Rituximab, conditioning chemotherapy plus CAR T-cells- Dose expansion
Intervention type:
Drug
Intervention name:
Fludarabine
Description:
30 mg/m^2 IV infusion over 30 minutes administered immediately following the
cyclophosphamide on days -5, -4,and -3
Arm group label:
1/Rituximab, conditioning chemotherapy plus CAR T-cells- Dose escalation
Arm group label:
2/Rituximab, conditioning chemotherapy plus CAR T-cells- Dose expansion
Intervention type:
Drug
Intervention name:
Rituximab
Description:
500 mg/m2 IV infusion over 30 minutes on day -5; 375 mg/m2 IV infusion over 30 minutes on
days 2-9 prior to apheresis
Arm group label:
1/Rituximab, conditioning chemotherapy plus CAR T-cells- Dose escalation
Arm group label:
2/Rituximab, conditioning chemotherapy plus CAR T-cells- Dose expansion
Summary:
Background:
Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) are blood cancers
that affect certain white blood cells. Advanced forms of these diseases are difficult to
treat. CD19 is a protein often found on the surfaces of these cancer cells. Researchers
can modify a person's own immune cells (T cells) to target CD19. When these modified T
cells are returned to the body-a treatment called anti-CD19 chimeric antigen receptor
(CAR) T cell therapy-they may help kill cancer cells.
Objective:
To test anti-CD19 CAR T cell therapy in people with CLL or SLL.
Eligibility:
People aged 18 years and older with CLL or SLL that has not been controlled with standard
drugs.
Design:
Participants will be screened. They will have imaging scans and tests of their heart
function. If a sample of tissue from their tumor is not available, a new one may be
taken; the sample will be tested for CD19.
Participants will receive a drug to reduce the leukemia cells in their blood. Then they
will undergo apheresis: Blood will be taken from the body through a needle. The blood
will pass through a machine that separates out the T cells. The remaining blood will be
returned to the body through a different needle. The collected T cells will be gene
edited to make them attack cells with CD19.
Participants will take drugs to prepare them for treatment for 3 days. These drugs will
start 5 days before the treatment. Then their own modified CAR T cells will be returned
to their bloodstream. Participants will stay in the hospital for at least 9 days after
the treatment.
Follow-up visits will continue for 5 years.
Detailed description:
Background:
- Improved treatments for relapsed and refractory chronic lymphocytic leukemia (CLL)
are needed.
- T cells can be genetically modified to express chimeric antigen receptors (CARs)
that specifically target malignancy-associated antigens.
- Autologous T cells genetically modified to express CARs targeting the B-cell antigen
CD19 have caused complete remissions in patients with leukemia or lymphoma. However,
there is no FDA-approved CAR T-cell product for CLL. Responses to CAR T-cell therapy
in CLL have historically been lower than in other B-cell malignancies.
- CD19 is uniformly expressed on CLL.
- CD19 is not expressed by normal cells except for B cells, follicular dendritic
cells, and some plasma cells.
- We have constructed a novel gene therapy construct that encodes a fully-human
anti-CD19 CAR.
- The conditioning regimen for this trial will include rituximab, fludarabine, and
cyclophosphamide.
- Possible toxicities include cytokine-associated toxicities such as fever,
hypotension, and neurological toxicities. Elimination of normal B cells is probable,
and unknown toxicities are also possible.
Primary objective, Phase I:
-Determine the safety of administering a novel conditioning regimen and T cells
expressing the Hu19-CD828Z CAR to participants with advanced CLL.
Primary objective, Phase II:
-Determine the overall response rate (ORR) of a novel conditioning regimen and T cells
expressing the Hu19-CD828Z CAR for participants with advanced CLL.
Eligibility:
- Participant must have CLL or small lymphocytic lymphoma (SLL).
- Age >= 18 years of age at time of enrollment
- Participant must have malignancy that is measurable on a CT scan or by flow
cytometry of bone marrow or blood.
- Participant must have a creatinine of 1.5 mg/dL or less and a normal cardiac
ejection fraction.
- An ECOG performance status of 0-1 is required.
- No active infections are allowed including hepatitis B or hepatitis C.
- Absolute neutrophil count >= 1000/microL, platelet count >= 50,000/microL,
hemoglobin >= 8g/dL
- Serum ALT and AST less or equal to 3 times the upper limit of the institutional
normal unless liver involvement by malignancy is demonstrated.
- At least 14 days must elapse between the time of any prior systemic treatment
(including corticosteroids) and the first dose of protocol-required rituximab. In
addition, 60 days must elapse from therapy with antibody-based treatments targeting
CD19 and CAR T-cell infusion.
- Prior CAR T-cell therapy is not allowed.
- Demonstration of CD19 expression by the CLL/SLL is required for eligibility.
- CD19 expression must be uniform . Uniform CD19 expression is defined as no obvious
CD19-negative CLL/SLL being present.
Design:
- This is a phase I dose-escalation trial with an expansion cohort (Phase II portion)
- T cells obtained by leukapheresis will be genetically modified to express the
Hu19-CD828Z CAR.
- Participants will receive 2 doses of rituximab and a lymphocyte-depleting
chemotherapy conditioning regimen with the intent of decreasing the burden of CLL,
which might reduce toxicity and improve anti-leukemia outcomes.
- Rituximab will be given in 2 doses, of 375 mg/m^2 for the first dose and 500 mg/m^2
for the second dose.
- The chemotherapy conditioning regimen is cyclophosphamide 500 mg/m^2 daily for 3
days and fludarabine 30 mg/m^2 daily for 3 days. Fludarabine will be given on the
same days as the cyclophosphamide.
- Three days after the chemotherapy ends, participants will receive an infusion of CAR
T cells.
- The initial dose level of this dose-escalation trial will be 1.0x10^6 CAR+ T
cells/kg of recipient bodyweight.
- The CAR T-cell cell dose administered will be escalated until a maximum tolerated
dose or an optimal dose is determined.
- Following the T-cell infusion, there is a mandatory 9-day inpatient hospitalization
to monitor for toxicity.
- Outpatient follow-up is planned for 2 weeks and 1, 2, 3, 4, 6, 9, and 12 months
after the CAR T-cell infusion; less frequent follow-up is required more than 1 year
after infusion. Long-term gene-therapy follow-up for a total of 15 years after
infusion is required.
Criteria for eligibility:
Criteria:
- INCLUSION CRITERIA:
- Malignancy criteria
- Histologically confirmed participants with either CLL or SLL will be eligible.
- Demonstration of CD19 expression on CLL/SLL, as assessed by the NCI Laboratory
of Pathology or NIH Department of Laboratory Medicine Hematopathology section.
- CD19 expression must be uniform meaning no populations of clearly CD19-negative
CLL/SLL cells are observed.
- Participants must have received prior systemic therapy. The last dosage of
systemic therapy (including corticosteroids) must be at least 14 days prior to
the first dose of rituximab.
- For participants who have received antibodies targeting CD19, at least sixty
days must elapse between therapy with antibodies targeting CD19 and CAR T-cell
infusion.
- Participants must have received at least two prior treatment regimens at least
one of which must have contained a Bruton s tyrosine kinase (BTK) inhibitor.
Participants who took a BTK inhibitor but stopped due to intolerance are
potentially eligible.
- All participants must have measurable malignancy as defined by at least one of
the criteria below.
- Presence of CLL or SLL masses that are measurable (minimum 1.5 cm in
largest diameter) by CT scan is required unless bone marrow or blood
involvement with malignancy is detected. All masses must be less than or
equal to 10.0 cm in the largest diameter.
- For CLL with only bone marrow and/or blood involvement, no mass is
necessary, but if a mass is not present, bone marrow and/or blood
malignancy must be detectable by flow cytometry. Any level of CLL
detectable by flow cytometry is sufficient for enrollment.
- Other inclusion criteria:
- Age >= 18 years.
- Performance status (ECOG) 0-1.
- Participants must have adequate organ and marrow function as defined below:
- ANC >= 1,000/mcL without the support of filgrastim or other growth factors
in the 10 days prior to enrollment
- platelets >= 50,000/mcL without transfusion support
- hemoglobin >= 8 g/dL
- total bilirubin <= 2.0 mg/dL
- ALT or AST Serum ALT and AST less or equal to 3 times the upper limit of
the institutional normal unless liver involvement by malignancy is
demonstrated. If liver involvement with malignancy is detected, ALT and
AST must be less than or equal to 5 times the upper limit of normal
- Serum Creatinine Serum creatinine levels < 1.5 X institutional ULN.
Participants with serum creatinine >= 1.5 X institutional ULN may
participate if serum creatinine eGFR is >=50 mL/min/1.73m^2 by 2021
CKD-EPI equation.
- ALT (SGPT)=alanine aminotransferase (serum glutamic pyruvic
transaminase);
- AST (SGOT)=aspartate aminotransferase (serum glutamic oxaloacetic
transaminase); GFR=glomerular filtration rate; ULN=upper limit of
normal.
- (A)Creatinine clearance (CrCl) or eGFR should be calculated per
institutional standard.
- B cells must make up less than 90% of blood lymphocytes on a lymphocyte
phenotyping profile TBNK at the time of enrollment.
- Room air oxygen saturation of 92% or greater
- Participants of child-bearing or child-fathering potential must be willing to
practice abstinence or highly effective contraception from the time of
enrollment on this study and for 12 months after receiving the protocol
treatment, or until CAR T cells are no longer detectable in the blood,
whichever is later.
- Participants must agree not to donate eggs for 12 months after receiving the
protocol treatment, or until CAR T cells are no longer detectable in the blood,
whichever is later.
- Participants who are breastfeeding must be willing to cease breastfeeding from
time of enrollment until 6 months after receiving treatment, or until CAR T
cells are no longer detectable in the blood, whichever is later.
- Participants must have a negative blood PCR test for hepatitis B DNA. If
hepatitis B DNA (PCR) testing is not available, participants must have a
negative hepatitis B surface antigen and negative hepatitis B core antibody
test.
- Participants must have a negative blood PCR test for hepatitis C RNA. Only if
Hepatitis C PCR testing is not available in a timely manner, participants must
have a negative Hepatitis C antibody test.
- Cardiac ejection fraction of greater than or equal to 50% by echocardiography
and no evidence of hemodynamically significant pericardial effusion as
determined by an echocardiogram within 30 days prior to treatment start.
- All participants must have the ability to understand and willingness to sign a
written informed consent.
- All participants must be willing to undergo mandatory biopsies during the
study. A bone marrow biopsy will be required prior to the chemotherapy and CAR
T-cell infusion. Another bone marrow biopsy will be required approximately 14
days after CAR T-cell infusion.
EXCLUSION CRITERIA:
- Participants who are receiving any other investigational agents.
- Participants who have had prior CAR T-cell therapy.
- Participants who have had a live-attenuated or viral vector-based vaccine in the
last 60 days prior to pre-leukapheresis rituximab. Participants who plan to receive
a live attenuated or viral vector-based vaccine within the first 100 days after CAR
T-cell infusion.
- Participants that require urgent therapy due to tumor mass effects or spinal cord
compression.
- Participants that have active hemolytic anemia.
- Current/active HIV infection, as measured by seropositivity for HIV antibody.
- Participants with second malignancies in addition to their CLL are not eligible if
the second malignancy has required treatment with surgery, radiation or
chemotherapy, or other therapies within the past 3 years or is not in complete
remission. Exceptions are that, in the last 3 years, participants may have had
successful resection of nonmetastatic basal cell or squamous cell carcinoma of the
skin, and participants may have received hormonal therapy for fully resected breast
cancer.
- Positive beta Human chorionic gonadotropin (Beta-HCG) serum or urine pregnancy test
in women of childbearing potential (WOCBP) performed at screening.
- Active uncontrolled systemic infections (defined as infections causing fevers within
48 hours of the date of planned protocol rituximab or chemotherapy start and
infections requiring intravenous antibiotics when intravenous antibiotics have been
administered for less than 72 hours at the time of protocol rituximab or
chemotherapy start). There must be objective evidence of infection, including, but
not limited to, a positive blood, urine or sputum culture, positive nasal swab or
blood test for viral infection, or the appearance of infiltrates on imaging of the
lung.
- Active coagulation disorders or other major uncontrolled medical illnesses of the
cardiovascular, respiratory, endocrine, renal, gastrointestinal, genitourinary or
immune system, history of myocardial infarction, history of ventricular tachycardia
or ventricular fibrillation, active cardiac arrhythmias (Resolved atrial
fibrillation that is not treated with anticoagulants is allowed.), active
obstructive or restrictive pulmonary disease, active autoimmune diseases such as
rheumatoid arthritis.These include uncontrolled intercurrent illness manifesting as
electrolyte derangements or as assessed by chemistries.
- Significant neurologic disorders, including a history of a seizure disorder as an
adult, that are not completely and permanently resolved and not requiring current
treatment.
- Any form of primary immunodeficiency (such as Severe Combined Immunodeficiency
Disease).
- Prior allogeneic stem cell transplant
- Systemic corticosteroid steroid therapy of any dose greater than 5 mg/day or more of
prednisone or equivalent is not allowed within 14 days prior to the first dose of
rituximab. Corticosteroid creams, ointments, and eye drops are allowed.
- Participants on systemic anticoagulant therapy except aspirin.
- History of severe immediate hypersensitivity reaction to any of the agents used in
this study, including hypersensitivity to aminoglycoside antibiotics, which may be
used in the cell culture media.
- Active central nervous system/brain metastases or cerebrospinal fluid malignancy.
- Checkpoint inhibitor drugs such as pembrolizumab or nivolumab or other antibodies
targeting PD-1 or PDL-1 within 180 days of protocol enrollment. This is because of
possible effects checkpoint inhibitor therapy could have on the participant's T
cells.
- Known active alcohol or drug abuse.
- History of allergy to study drug components.
- Active tumor lysis syndrome as assessed by serum uric acid, LDH, calcium, and
phosphorus.
- Active rhabdomyolysis as assessed by elevated CK and acute change in renal function
as reflected by increased creatinine and blood urea nitrogen (BUN).
- Active diabetic ketoacidosis or hyperosmolar hyperglycemic state, as assessed by
serum glucose. The urine will be tested for ketones if serum glucose is over 350
mg/dL at screening.
Gender:
All
Minimum age:
18 Years
Maximum age:
120 Years
Healthy volunteers:
No
Locations:
Facility:
Name:
National Institutes of Health Clinical Center
Address:
City:
Bethesda
Zip:
20892
Country:
United States
Status:
Recruiting
Contact:
Last name:
NCI Medical Oncology Referral Office
Phone:
240-760-6050
Email:
ncimo_referrals@nih.gov
Contact backup:
Last name:
Micaela Ganaden, M.D.
Phone:
(240) 858-3654
Email:
ncicar@mail.nih.gov
Start date:
September 3, 2024
Completion date:
July 1, 2030
Lead sponsor:
Agency:
National Cancer Institute (NCI)
Agency class:
NIH
Source:
National Institutes of Health Clinical Center (CC)
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT06364423
https://clinicalstudies.info.nih.gov/cgi/detail.cgi?A_001599-C.html
